YY1 and breast carcinoma: In the background of hormone therapy aimed at inhibiting estrogen production in breast cancer, YY1 contributes to clonal selection by maintaining the binding of ERα-YY1 to the enhancer of SLC9A3R1, a hormone therapy-resistant gene.